Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00423
|
|||||
| Drug Name |
Gefitinib
|
|||||
| Synonyms |
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine; CU-00000000396-1; Gefitini; Gefitinib (JAN/USAN/INN); Gefitinib [USAN]; Gefitinib,Iressa, ZD1839; IRE; Iressa; Iressa (TN); Iressa(TM); Irressat; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; ZD 1839; ZD-1839; ZD-1839, Iressa, Gefitinib; ZD1839
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Breast cancer [ICD11:2C60-2C6Z] | Approved | [1] | |||
| Urethral cancer [ICD11:2F78] | Approved | [1] | ||||
| Non-small cell lung cancer [ICD11:2C25] | Approved | [1] | ||||
| Ovarian cancer [ICD11:2C73] | Preclinical | [1] | ||||
| Prostate cancer [ICD11:2C82] | Preclinical | [1] | ||||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C22H24ClFN4O3
|
|||||
| Canonical SMILES |
COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
|
|||||
| InChI |
InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
|
|||||
| InChIKey |
XGALLCVXEZPNRQ-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 184475-35-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 446.9 | Topological Polar Surface Area | 68.7 | ||
| Heavy Atom Count | 31 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
4.1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10240807
,103024897
,10318995
,103244983
,103905343
,103905344
,104418951
,104829175
,11377941
,117865087
,118047033
,12015033
,123105108
,124756943
,124892204
,124892205
,124892206
,125001914
,14833109
,21317853
,24424016
,24424024
,24424026
,29215403
,29215404
,29303859
,46508649
,47646567
,49635529
,49742641
,50040863
,50100103
,532631
,53319998
,53788589
,53799235
,56312091
,56313236
,56313469
,57340492
,61127928
,7849039
,8035066
,81092810
,85171051
,92308715
,92717784
,93581024
,99436946
,99444469
|
|||||
| ChEBI ID |
ChEBI:49668
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [3] | ||
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [3] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [4] | ||
| References | ||||||
| 1 | Gefitinib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
| 3 | Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66. | |||||
| 4 | Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol. 2009 Aug;68(2):226-37. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.